Summary & Overview

Cervical Spinal Fusion with MCC: Inpatient Reimbursement Overview

DRG 471 represents cervical spinal fusion procedures with Major Complication or Comorbidity and encompasses higher-severity cervical spine surgery cases. It matters for inpatient reimbursement because assignment to this Diagnosis-Related Group increases payment to reflect greater resource intensity and complexity of care under Medicare.

Cervical Spinal Fusion with MCCDRG Cervical Spinal Fusion with MCCDRG 471Diagnosis-Related GroupInpatient ReimbursementMedicareSpine SurgeryOrthopedicNeurosurgery

DRG 471 Overview

DRG 471 covers inpatient episodes involving cervical spinal fusion procedures with the presence of a Major Complication or Comorbidity, indicating higher clinical severity and resource use. This Diagnosis-Related Group is important for Medicare payment because cases assigned here typically qualify for higher reimbursement relative to uncomplicated fusions, reflecting increased costs for intensive care, longer operating room time, and greater post-operative needs. Accurate coding of diagnoses and procedures determines assignment to DRG 471 and influences payment under inpatient prospective payment systems.

National Payment Rates

Across commercial payers the benchmark rates for DRG 471 range from about $370 to $180K, with payer medians spanning roughly $41K to $74K; the widest spread observed is between Anthem (max $180K) and BCBS (min $370), a spread of about $179.6K. See the table and chart below for payer-specific quartiles and distribution. Payers included are Blue Cross Blue Shield, UnitedHealth Group, Cigna, Aetna, and Anthem.

Mean Rates by Payer — National — DRG 471

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s DRG 471 reimbursement ranges from $75K (Blue Cross Blue Shield and Anthem) up to $120K (Cigna), representing a notable spread across payers. Cigna’s $120K mean sits well above typical national averages, while BCBS and Anthem are clustered at the lower bound. See the table and chart below for payer-level detail.

Key Insights for Alaska

Highest payer: Cigna at $120K; Lowest payers: BCBS and Anthem both at $75K.
Cigna’s mean of $120K is meaningfully above typical national means for major payers, indicating Alaska’s upper-end reimbursement for DRG 471 is substantially higher than national averages.

Clinical Trials

Acute surgical technique and intraoperative neuroprotection studies: randomized or controlled studies comparing specific surgical approaches, fusion levels, or intraoperative adjuncts (for example, anterior versus posterior approaches, use of expandable versus static cages, or adjuncts aimed at reducing intraoperative neurological injury) in patients undergoing cervical spinal fusion with major complications/comorbidities. These trials focus on the intraoperative and immediate perioperative period in a high-risk population—often older adults with complex degenerative disease, trauma, infection, or multi-system comorbidity—and assess outcomes such as operative complications, neurologic status, blood loss, and length of stay. This research is relevant to providers and payers because improved intraoperative strategies can reduce MCC-related morbidity, shorten hospitalization, and lower acute care costs associated with this DRG.
Comparative effectiveness and risk-stratification studies of fusion versus motion-preserving or less extensive procedures: prospective cohort studies or pragmatic trials evaluating longer-term functional outcomes, reoperation rates, and complication profiles in patients with cervical pathology and major comorbid conditions who are candidates for fusion versus alternative surgical or minimally invasive approaches. These studies typically enroll patients with significant baseline risk (eg, severe myelopathy, multilevel degenerative disease, prior cervical surgery, or cardiopulmonary comorbidity) to determine which interventions yield the best balance of durability, neurologic recovery, and resource utilization over 1–5 years. Findings inform clinical decision-making and payer coverage policies by identifying which procedures offer the most favorable outcomes relative to cost and by supporting stratified care pathways for high-risk DRG 471 patients.
Post-discharge outcomes, rehabilitation, and readmission prevention research: observational studies and intervention trials examining inpatient-to-outpatient transition models, tailored rehabilitation protocols, and peri-discharge care bundles for patients discharged after cervical fusion with major complications. These investigations target the early post-discharge period in patients with MCC who are at elevated risk for readmission, wound complications, hardware issues, and persistent neurologic deficits; they evaluate measures such as functional recovery, pain control, secondary complications, readmission rates, and total 90-day episode costs. The results are valuable to providers and payers because optimized discharge planning and post-acute care can reduce preventable readmissions, improve recovery trajectories, and lower overall expenditures associated with this high-acuity DRG.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$48K	$230K	$41K	3.2K

Acute surgical technique and intraoperative neuroprotection studies: randomized or controlled studies comparing specific surgical approaches, fusion levels, or intraoperative adjuncts (for example, anterior versus posterior approaches, use of expandable versus static cages, or adjuncts aimed at reducing intraoperative neurological injury) in patients undergoing cervical spinal fusion with major complications/comorbidities. These trials focus on the intraoperative and immediate perioperative period in a high-risk population—often older adults with complex degenerative disease, trauma, infection, or multi-system comorbidity—and assess outcomes such as operative complications, neurologic status, blood loss, and length of stay. This research is relevant to providers and payers because improved intraoperative strategies can reduce MCC-related morbidity, shorten hospitalization, and lower acute care costs associated with this DRG.
Comparative effectiveness and risk-stratification studies of fusion versus motion-preserving or less extensive procedures: prospective cohort studies or pragmatic trials evaluating longer-term functional outcomes, reoperation rates, and complication profiles in patients with cervical pathology and major comorbid conditions who are candidates for fusion versus alternative surgical or minimally invasive approaches. These studies typically enroll patients with significant baseline risk (eg, severe myelopathy, multilevel degenerative disease, prior cervical surgery, or cardiopulmonary comorbidity) to determine which interventions yield the best balance of durability, neurologic recovery, and resource utilization over 1–5 years. Findings inform clinical decision-making and payer coverage policies by identifying which procedures offer the most favorable outcomes relative to cost and by supporting stratified care pathways for high-risk DRG 471 patients.
Post-discharge outcomes, rehabilitation, and readmission prevention research: observational studies and intervention trials examining inpatient-to-outpatient transition models, tailored rehabilitation protocols, and peri-discharge care bundles for patients discharged after cervical fusion with major complications. These investigations target the early post-discharge period in patients with MCC who are at elevated risk for readmission, wound complications, hardware issues, and persistent neurologic deficits; they evaluate measures such as functional recovery, pain control, secondary complications, readmission rates, and total 90-day episode costs. The results are valuable to providers and payers because optimized discharge planning and post-acute care can reduce preventable readmissions, improve recovery trajectories, and lower overall expenditures associated with this high-acuity DRG.

OpenPayer

Summary & Overview

Cervical Spinal Fusion with MCC: Inpatient Reimbursement Overview

DRG 471 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes